more

Protagonist Therapeutics (PTGX)

(Delayed Data from NSDQ)

$26.09 USD

+0.55 (2.15%)

Updated May 3, 2024 04:00 PM ET

After-Market: $26.07 -0.02 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Perrigo (PRGO) Misses on Earnings in Q1, Reiterates View

by Zacks Equity Research Published on May 08,2018

Perrigo (PRGO) misses earnings estimates but exceeds revenue expectations in Q1. The company reiterates its revenue and adjusted earnings outlook for 2018.

Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss

by Zacks Equity Research Published on May 07,2018

Agios (AGIO) incurs wider-than-expected loss and misses revenue estimates in Q1. The first quarter highlights the FDA's acceptance of the NDA for Tibsovo.

AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View

by Zacks Equity Research Published on May 04,2018

AMAG incurs wider-than-expected loss in the first quarter of 2018. The company raised 2018 revenue guidance.

Spectrum (SPPI) Earnings and Sales Beat Estimates in Q1

by Zacks Equity Research Published on May 04,2018

Spectrum (SPPI) reports narrower-than-expected loss in the first quarter and also beat revenues. Rolontis successful in phase III study.

Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Impress

by Zacks Equity Research Published on May 04,2018

Sarepta (SRPT) reports narrower-than-expected loss for the first quarter of 2018. However, sales miss estimates.

Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1

by Zacks Equity Research Published on May 03,2018

Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in Q1. The company remains on track to start a pivotal phase III study for CMB305 on patients with synovial sarcoma.

Bayer (BAYRY) Misses Earnings and Revenue Estimates in Q1

by Zacks Equity Research Published on May 03,2018

Bayer (BAYRY) misses first-quarter 2018 earnings and sales estimates.

Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO

by Zacks Equity Research Published on May 03,2018

Achillion Pharmaceuticals (ACHN) disappoints with wider-than-expected loss in the first quarter. Appoints Joseph Truitt as new CEO.

Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss

by Zacks Equity Research Published on May 02,2018

Novo Nordisk's (NVO) first-quarter 2018 results beat earnings, but missed on revenue estimates.

Zoetis (ZTS) Beats on Q1 Earnings & Sales, Retains '18 View

by Zacks Equity Research Published on May 02,2018

Zoetis (ZTS) exceeds both earnings and sales expectations in the first quarter of 2018.

Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1

by Zacks Equity Research Published on April 27,2018

Alkermes (ALKS) posts wider than expected loss in the first quarter of 2018. However, sales beat estimates.

Shire (SHPG) Q1 Earnings Beat, Rare Disease Franchise Strong

by Zacks Equity Research Published on April 27,2018

Shire (SHPG) reports better-than-expected first-quarter earnings and records strong growth in immunology franchise and newly launched products.

Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales

by Zacks Equity Research Published on April 27,2018

Vertex Pharma (VRTX) first-quarter earnings increase from the year-ago period led by strong sales trend of CF drugs.

Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up

by Zacks Equity Research Published on April 26,2018

Alexion exceeds both earnings and sales expectations in the first quarter of 2018.The company also raised revenue and earnings guidance for 2018.

Catalyst Enrolls First Patient in Phase III Firdapse Study

by Zacks Equity Research Published on April 20,2018

Catalyst (CPRX) enrolls the first patient in its phase III clinical trial (MSK-002) to evaluate the efficacy and safety of Firdapse in patients with MuSK antibody positive Myasthenia Gravis.

Bayer to Divest 3.6% Stake to Singapore Company Temasek

by Zacks Equity Research Published on April 18,2018

Bayer (BAYRY) will divest its 3.6% stake to Singapore's state investment company Temasek for total gross proceeds of ???3 billion.

U.S. Markets Close Highest in a Month: 4 Momentum Picks

by Nalak Das Published on April 18,2018

Stock market momentum will persist as first-quarter earnings have so far have been better than expected and several big companies are yet to release results.

Alnylam (ALNY) Reports Positive Data for RNAi Candidate

by Zacks Equity Research Published on April 17,2018

Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias.

Alkermes Rallies as FDA Accepts NDA for Depression Drug

by Zacks Equity Research Published on April 17,2018

Shares of Alkermes (ALKS) rose when the FDA accepted for review the new drug application for its depression candidate ALKS 5461 two weeks after it had issued a Refusal to File letter.

Intercept Reports Phase III Sub-Study Liver Biopsy Data

by Zacks Equity Research Published on April 16,2018

Intercept (ICPT) announces data from the POISE biopsy sub-study which showed that treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis.

Here's Why Geron Stock Surged More Than 90% in 6 Months

by Zacks Equity Research Published on April 13,2018

Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.